PsiloThera, Inc. offering is now closed and is no longer accepting investments.
INVEST IN PSILOTHERA, INC. TODAY!
Psychedelic Healthcare Innovation
$173,121.29 Raised
REASONS TO INVEST
Psilothera is stepping into the scene of major healthcare crisis by focusing on medical research breakthroughs and groundbreaking legalizations
The company is actively targeting a $100 billion market opportunity in Psilocybin healthcare
Psilothera is led by a battle tested management team with business model, strategy and plan driven by research and development
The Problem
The world is in the throes of a mental health crisis
Recent estimates from the World Health Organization show that roughly 322 Million People suffer from Major Depression Disorder. In the US alone, 16 million people suffer from this debilitating disease. What’s worse is that up to a third of the people suffering from clinical depression are “treatment resistant,” meaning traditional antidepressants don’t treat them. This resistance is one of the reasons why 17.6 veterans commit suicide a day in the United States. With the current state of the mental healthcare industry, they have no other options for medication.
A recent Gallup poll shows that the pharmaceutical industry is the least trusted industry in America. Toxic industry norms, widespread corruption, as well as harsh side effects of mental health medicine have created a need for a viable alternative among patients and consumers. (Source)
THE SOLUTION
Psilocybin-based therapy is revolutionizing the world of mental healthcare
Psilothera commits to providing new remedies for mental wellness by creating compounds for Psilocybin-based treatments. Psilocybin assisted therapy gives the patient the opportunity to fully engage in self-reflection and personal expression, ultimately shift emotional and behavior patterns.
The technique used in Psilocybin assisted therapy is microdosing. Microdosing is the regular intake of very small quantities of psychedelic substances. Microdosing is beneficial because while there are minimal acute effects reported, these substances claim a range of long-term health and well-being benefits. We believe the fear of having a “bad trip” on Psilocybin makes microdosing a more approachable option for the millions of people suffering.
THE MARKET
Vertical integration powered by quantum technology
Psilothera’s battle tested leadership team is made up of entrepreneurs, mental health professionals, and mushroom farmers. This team agrees on the same mission: be one of the first companies focused on developing Psilocybin-based therapeutics while deploying quantum technology. We are currently in the final stages of procuring a technology licensing agreement with a well-known quantum technology company, which will drastically reduce the development time as well as the cost of therapeutics.
OUR TRACTION
Gaining momentum by the day
Breakthrough studies by reputable programs such as Journal of JAMA Psychiatry, Johns Hopkins Center for Psychedelic & Consciousness Research, Imperial College, and US National Library of Medicine National Institute of Health have all shown promising results on psychedelics’ ability to treat long-lasting depressive, PTSD, and anxiety symptoms with minimal side effects.
Psilothera’s partnership with the Zoom Healthcare ISV Program to develop its tele-health mental health care video platform is paving the way for groundbreaking development in online Psilocybin-based treatment.
Psilothera is pre-revenue and our Fungi Grow & Lab is in its pre-launch stage. Once launched, the lab will begin researching, growing, and developing 20 different types of Psilocybe Cubensis, providing us with a robust portfolio of therapeutic fungi.
The varieties of mushrooms to be used in our formulations include Reishi, Lion’s Mane, Turkey Tail, Shiitake, Maitake, and Oyster. Reishi, for example, is being studied and used for its anticancer potential at the Memorial Sloan Kettering Cancer Center. Our Mushroom Nutraceutical product line for cancer patients is designed to support their current treatments program.
On a global scale, in November 2020, Oregon became the first state in the United States to legalize Psilocybin, allowing supervised use of psilocybin in a therapeutic setting.
Furthermore, voters around the country have decriminalized in Washington DC, Denver, Oakland, Ann Arbor, Houston, Somerset and Cambridge, MA so far. Psilothera projects widespread movement towards Legalization and Decriminalization by 2023.
WHY INVEST
The time to invest is now
A major paradigm shift is occurring in the healthcare sector. Breakthrough medical studies, a string of groundbreaking legalizations, and an unprecedented public openness to psychedelics has paved the road for Psilocybin-based therapy to be a legitimate alternative to pharmaceutical products. Psilothera aims to deploy this cutting edge medicine to establish itself as a beacon of hope, wellness, and compassion in the mental health market.
gif
Annual sales for antidepressants, ADHD, anxiety, and anti-addiction medications well exceed $30 billion, and an increasing number of studies are showing a potential for Psilocybin and other psychedelic-based therapies to be as or even more effective than their pharmaceutical counterparts, meaning potential billions in revenue.
Our mushrooms aren't magic. They're therapeutic, backed by science. We believe they're the future of mental health treatment.
ABOUT
HEADQUARTERS
17 Cerchio Basso
Henderson, NV 89011
VALUATION
$50M
Psilothera is a pioneering mental health care company dedicated to creative, modern solutions to treat global healthcare concerns, including depression, anxiety, PTSD, eating disorders, addictions, Alzheimer’s, dementia, and more. We plan to deploy quantum technology to shorten the drug development time, which will give us an advantage over our competitors. With a focus on healing, hope, and compassion, we aim to change the paradigm of mental healthcare with their Psilocybin-based therapies.
TEAM
John Atanasio
CEO and Founder
Jacquelyn Wright-Minogue
Advisor- Clinical Trials & Founder
"Chaplain Chuck" Atanasio
Director of Research, Psychologist, Retired Army Major, Chaplain & Behavioral Specialist
Michelle Pon Tell
Head Therapist-Advisor
Michelle is a Certified Clinical Trauma Professional, clinically trained in Somatic Experiencing, a method ideally suited to gently releasing the stress, anxiety, trauma and overwhelm trapped in one's body. This powerful modality allows clients to quickly resolve past emotional issues so they can move forward with a sense of joy and freedom.
Her experiences working with Hospice, as well as providing intensive in-home therapy to families, has allowed Michelle the humbling privilege of walking with all types of individuals through some of life's most difficult circumstances. Whatever your situation, she is available to meet you where you are and help you get to where you want to be.
Jan Rydfords
Doctor- Medical Advisor
Holly Scott
Director of Fungi Grow & Cultivation
Anthony Baldassari
Behavioral Analyst
Adam Bell
Creative Director- Web Design & Strategy
Dan Vosler
Director of IT
Leif Rydfors
Patient Advocate - Spokesperson
Spike Humer
Business Development & Strategy
Howard "Mystro' Stroman
Business Development & Strategy
Professionally Mystro is a. Music & Entertainment Industry Executive and iconic Vegas Music Director & Performer. He is a serial entrepreneur with business interests in the areas of Music Production, Internet + Technology, Craft Spirits, Cannabis, CBD & Quantum Technology.
Glen Biondi, Esq.
Legal Advisor
Ed Galisewski
Spiritual Advisor
Anthony Amatucci
Legislative Analyst
TERMS
PsiloThera, Inc.
Overview
PRICE PER SHARE
$5
DEADLINE
Mar 19, 2022
VALUATION
$50M
AMOUNT RAISED
$173,121.29
Breakdown
MIN INVESTMENT
$500.00
MAX INVESTMENT
$107,000.00
MIN NUMBER OF SHARES OFFERED
2,000
OFFERING TYPE
Equity
ASSET TYPE
COMMON
SHARES OFFERED
Common Stock
MAX NUMBER OF SHARES OFFERED
1,000,000
Maximum Number of Shares Offered subject to adjustment for bonus shares
Company | : | PsiloThera, Inc. |
Corporate Address | : | 17 Cerchio Basso, Henderson, NV 89011 |
Offering Minimum | : | $10,000.00 |
Offering Maximum | : | $5,000,000.00 |
Minimum Investment Amount(per investor) | : | $500.00 |
Terms
Offering Type | : | Equity |
Security Name | : | Common Stock |
Minimum Number of Shares Offered | : | 2,000 |
Maximum Number of Shares Offered | : | 1,000,000 |
Price per Share | : | $5.00 |
Pre-Money Valuation | : | $50,000,000.00 |
*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below. Note these perks do stack with the other offering perks. You will only receive the highest level bonus share perk you are eligible for.
Company Perks*
Time-Based Perks
Friends & Family Bonus
Invest in the first 72 hours and receive 10% bonus shares.
Amount-Based Perks
Tier 1: $50,000+
Invest $50,000 or more and receive 5% bonus shares
Tier 2: $75,000+
Invest $75,000 or more and receive 7% bonus shares
Tier 3: $100,000+
Invest $100,000 or more and receive 10% bonus shares
*All perks occur when the offering is completed.
The 10% StartEngine Owners' Bonus
Psilothera will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.
This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $5.00 / share, you will receive 110 shares of Common Stock, meaning you'll own 110 shares for $500. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.
This 10% Bonus is only valid during the investors' eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are cancelled or fail.
Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.
Irregular Use of Proceeds
The Company will not incur any irregular use of proceeds.
ALL UPDATES
03.22.22
Psilothera + PolarisQB Sign Agreement to Launch Quantum, Ai + Machine Learning Technologies for Drug Discovery Platform.
Psilothera Important Update
Thanks to all Investors
Psilothera + PolarisQB Sign Agreement to Launch Quantum, Ai + Machine Learning Technologies for Drug Discovery Platform.
Our treatment focus is Mental Illnesses and Cognitive Diseases.
According to Psilothera CEO, John Atanasio, "Polaris QB is an important Strategic Relationship & Resource of Psilothera's Drug Discovery & Development Platform."
Atanasio stated , "We shall deploy Polaris QB's Quantum Computing ,Ai + Machine Learning Technologies to identify unique opportunities for molecular discovery."
According to PolarisQB,
"We have built the first ever drug discovery platform using a quantum computer, making the discovery process ten times faster. Our platform and technology allow us to scan billions of molecules from a large chemical space, while keeping costs efficient.Without the need for multiple optimization cycles, we find the same (or better) molecules faster utilizing Quantum Computing, artificial intelligence, and machine learning."
03.18.22
Utah Senate Approved Psychedelic & Mental Health Bill - sent to Governor
Utah Senate on Friday approved a psychedelic and mental health bill that would create a Mental Illness Psychotherapy Drug Task Force to study and make recommendations on the therapeutic potential of psychedelic drugs. The bill, which is now heading to the governor’s desk for a signature, would also establish possible regulations for the legal use of psychedelic drugs Source Bezinga
Utah is added to a list of States that have recently intiated a legislative process that includes: California, New York, Florida Hawaii. Oregon has already decriminalized and legalized for Therapeutic use. Denver, Houston, Washington DC are among the earliest cities to decriminalize.
03.17.22
Psilothera Drug Discovery Pipeline- Target Receptors
Phase 1 Drug Discovery Platform
Diagnosis/ Serotonin Receptor (s)Targets
PTSD: 5HT2A
DEPRESSION: 5HT2AR, 5HT2A
ANXIETY: 5HT2A, 5HT1A, 5HT2C
ANOREXIA NERVOSA:5-HT2A, 5-HT1A, 5-HT2C
ANXIETY CO-MORBIDITY: 5HT2A, 5HT1A, 5HT2C
DEPRESSION CO-MORBIDITY: 5HT2AR, 5HT2A
OCD: 5HT1A, 5HT2A, 5HT2C
ADDICTIONS: 5HT2AR
AUTISTIC SPECTRUM DISORDER: 5-HT2A, 5-HT1A
ANXIETY CO-MORBIDITY: 5HT2A, 5HT1A, 5HT2C
SUBSTANCE USE DISORDER:5HT2A, 5HT2C
ANXIETY CO-MORBIDITY: 5HT2A, 5HT1A, 5HT2C
ALCOHOL USE DISORDER: 5HT2A
TOBACCO USE DISORDER: 5HT2A
END-OF-LIFE ANXIETY: 5HT2A, 5HT1A, 5HT2C
ALZHEIMER’S, DEMENTIA, COGNITIVE DECLINE: 5HT2A-R
Data currently being collected on Cocaine, Opioids and Methamphetamine
Chuck Atanasio, Director of Research
01.06.22
Notice of Material Change in Offering
[The following is an automated notice from the StartEngine team].
Hello! Recently, a change was made to the PsiloThera, Inc. offering. Here's an excerpt describing the specifics of the change:
The issuer is extending their campaign 59 days to 03/18/2022.
When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.
12.13.21
Psilothera & PsyRx Sign Important Agreement to Develop Natural Psychedelic Compounds
Hi Psilothera Investors,
Important Announcement
Psilothera & PsyRx Sign Agreement to Develop Natural Psychedelic Compounds.
PsyRx labs are located at Hebrew University in Tel Aviv, Israel and are licensed to develop naturally sourced Psychedelic Compounds. We shall collaborate with PsyRx to create GMP-Standard naturally sourced (Not Synthesized) Psilocybin, Ibogaine and other Psychedelic compounds when available using PsyRx’s Agro-Medical Bio Reactor.
Psilothera shall utilize these compound to develop innovative Therapeutics and treatments for Mental Illnesses and Cognitive Diseases.
John Atanasio, CEO
12.07.21
Psilothera Signs Agreement with Famous Shaman Inka Medicine Men to launch a healing retreat in Cuzco-Machu Picchu
Hi Psilothera Investors,
Psilothera gaining great traction in the market after our Wonderland- Miami Sponsorship. We are proud to announce this important company opportunity.
Psilothera is expanding into additional areas of Psychedelics beyond Psilocybin and is now looking at integrating other treatment options such as Ketamine, MDMA, DMT and LSD. The company plans to apply for a DEA Schedule 1 license for research and manufacturing.
Psilothera has signed an Agreement with Famous Shaman Inka Medicine Men to launch a Psilothera healing retreat in Cuzco-Machu Picchu.
Psilothera has exclusivepartnered with internationally recognized Shaman Inka Medicine Man K’uychi Florez Zevallos and his Son Luciano Florez Qquesihuallpa whom is a Psychologist and Shaman Inka Medicine Man.
K´uychi (Called Rainbow in his native Inka tongue “Quechua”) Born in Cusco, Peru. K’uychi holds an authentic blood and Inka lineage. K´uychi is a Shaman Inka Medicine Man, spiritualist, mystic, historian, researcher, poet and Peruvian politician. Since 1987, he has developed conferences and workshops throughout Asia, America and Europe. He is a University Professor, Master in Sciences who investigates and practices alternative therapies in a transpersonal, shamanic and holistic context. For the last 20 years, he´s been taking many groups of people to the jungle of Peru, leading them in shamanic experiences to treat and cure their mental and emotional illnesses, using the ancient jungle medicine, the sacred vine Ayahuasca DMT. Hundreds of people have awaken new states of consciousness, experienced a spiritual growth, enjoyed a new wellbeing and have discovered the real meaning of transcendence in their lives through the ceremonies and sacred rituals led by him. Nowadays K´uychi dedicates his great efforts to achieve the legitimacy of the legal therapeutic use of the DMT, and to stop the stigmatization of this divine plant that Mother Nature “Pachamama” with her immense love, has given to us, to whole humanity. His life’s mission is to spread the wisdom and medicine of the ancient Inka healers in all over the world. As shamans, we consider that DMT “The molecule of God” is one of the most powerful psychedelic that exist, its healing properties are limitless. DMT not only reaches your mind, goes even further into your heart and soul.
Please support our efforts and invest!
John Atanasio, CEO
12.01.21
Psilothera CEO John Atanasio to Speak at The Cannabis Investment Summit.- Feb 2nd
Hi Psilothera Investors
Psilothera CEO John Atanasio to Speak at The Cannabis Investment Summit.- Feb 2nd. Happy to be invited and this gives Psilothera another platform to share our story.
John Atanasio, CEO
12.01.21
Notice of Funds Disbursement
[The following is an automated notice from the StartEngine team].
Hello!
As you might know, PsiloThera, Inc. has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PsiloThera, Inc. be on the lookout for an email that describes more about the disbursement process.
This campaign will continue to accept investments until its indicated closing date.
Thanks for funding the future.
-StartEngine
11.30.21
Psilothera to Present at the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference - December 6, 2021.
Hi Startengine Investors,
Psilothera to Present at the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference - December 6, 2021.
This is a great platform to share our story.
We have over 400 investors watching on the Startengine.
We have outstanding momentum and please invest now.
John Atanasio, CEO
11.23.21
Psilothera's CEO John Atanasio on Stage at Wonderland Miami 2021-Video
Hi StartEngine Investors
Psilothera's CEO John Atanasio on Stage at Wonderland Miami 2021 Video
REWARDS
$500.00
StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.
$50,000.00
Tier 1: $50,000+
Invest $50,000 or more and receive 5% bonus shares
$75,000.00
Tier 2: $75,000+
Invest $75,000 or more and receive 7% bonus shares
$100,000.00
Tier 3: $100,000+
Invest $100,000 or more and receive 10% bonus shares
JOIN THE DISCUSSION
0/2500
HOW INVESTING WORKS
Cancel anytime before 48 hours before a rolling close or the offering end date.
WHY STARTENGINE?
REWARDS
We want you to succeed and get the most out of your money by offering rewards and memberships!
SECURE
Your info is your info. We take pride in keeping it that way!
DIVERSE INVESTMENTS
Invest in over 200 start-ups and collectibles!
With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.
With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.
At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.
Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.
StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.
For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.
For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.
Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.
Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.
Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.
